Resumo

MARTIN, Sívori  e  DANIEL, Pascansky. T2-High Severe Asthma: Analysis of the Design of Clinical Studies of New Biologics. Rev. am. med. respir. [online]. 2022, vol.22, n.1, pp.98-115. ISSN 1852-236X.

In the last years, the appearance of new monoclonal antibodies (biologics) for the treatment of T2-high severe asthma allowed us to use the few therapeutic tools we had to treat this group of patients, which is small but differs from the rest of the asthmatics in its management.

So far there are various publications supporting certain rules such as the Guidelines for Severe Asthma Management on a worldwide level, which were used by the different scientific societies for the development of those guidelines.

But the thorough reading of cited publications reveals clear differences regarding the methodology, use of variables and interpretation of the results.

Based on these premises, this work allows us to conduct a critical analysis of the phase III clinical studies of the development of biologics for severe asthma, taking into account the methodology and different variables that entail the published results.

Palavras-chave : Eosinophilic severe asthma; T2-high; Biologics; Monoclonal antibodies; Adherence.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )